Novartis loses patent claim in India

Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster cancer drug Glivec, arguing the compound was a significant improvement because it is more easily absorbed.

In a ruling that went to the heart of patent law in a country known as the "pharmacy to the world", the top court ruled on Monday that the compound "did not satisfy the test of novelty or inventiveness" required by Indian law.

This upheld the view of India's patent office, which refused to grant protection on the grounds that